The ML model (DynamiT), trained on simulation-derived structural and dynamical features extracted from 2500 time points, revealed key determinants responsible for T-cell activation with an accuracy of 73.3%.
Abstract
T-cell immunity acts as a major defense system against controlling viral infections in vertebrates. During viral entry, innate immune cells degrade the viral proteins (antigens) and present them on their surface via Major Histocompatibility (MHC) proteins. T-cell receptors (TCRs) recognize these antigens/peptides presented by MHC (pMHC), initiating a T-cell mediated immune response. Despite its significance, the mechanism by which pMHC-TCR binding triggers T-cell activation remains unclear. In this study, we employed an integrative computational approach combining Bioinformatics, Molecular Dynamics (MD) simulations, and Machine Learning (ML) to identify viral epitopes as potential vaccine candidates. We performed large-scale all-atom and coarse-grained MD simulations on MHC-peptide-TCR complexes embedded into dendritic and T-cells, for which experimental immunogenicity data is available. One hundred fifty such systems are simulated for 1 {\mu}s each to capture the conformational and dynamical changes that underlie T-cell activation. Our ML model (DynamiT), trained on simulation-derived structural and dynamical features extracted from 2500 time points, revealed key determinants responsible for T-cell activation with an accuracy of 73.3%. Notably, we have identified the bending of the TCR transmembrane region, major dynamic motions of the TCR{\alpha} constant region and the buried surface area at the pMHC and TCR interface as critical factors influencing immune response initiation. Our approach unravels the mechanism of T-cell mediated immune response and helps ML-guided screening of viral epitopes for vaccine development.
A mechanistic basis and a conceptual framework for the selection and optimization of TCRs for adoptive immunotherapy are provided for the selection and optimization of TCRs for adoptive immunotherapy.
Leire Oyon-Olea, Enric Vercher, M. G. Dichiara-Rodríguez et al.· bioRxiv· 0 citations
MHC restriction — the requirement for αβ T cell receptors (TCRs) to recognize Major Histocompatibility Complex (MHC) molecules when presenting peptide antigens — is a pillar of adaptive immunity. Here, we provide direct structural evidence for TCR germline-encoded recognition of MHC molecules irrespective of antigenic...
Nan Wang, Marta T. Borowska, K. Jude et al.· bioRxiv· 0 citations
Introduction Marburg virus (MARV) is a hemorrhagic fever virus, and its glycoprotein (GP) represents an important target for vaccine research. MHC class I (MHC-I)-restricted T cell epitopes are critical for inducing cytotoxic CD8+ T cell responses. In this study, we aimed to identify MHC-I-restricted T cell epitopes de...
Yu-Lin Yang, Jing Wang, En-Qi Guan et al.· Frontiers in Immunology· 0 citations
It is proposed that variation in specificity, defined as distinct epitope‐level responses across individuals, represents a largely untested critical element in the assessment of anti‐pathogen and antitumor immunity.
Single-chain variable fragments (scFvs) penetrate tissue more effectively than full antibodies and are simpler to produce, but the mutant proteins that define a tumor are predominantly intracellular and therefore inaccessible to conventional antibodies. What is accessible is the mutation-derived peptide displayed on ce...
S. Niazi, Matthias Magoola, Zamara Mariam· npj Drug Discovery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.